Renewal of Milner Therapeutics Consortium
We are delighted to announce that the Milner Therapeutics Consortium has been renewed until 2024. The Consortium includes 7 pharma companies (Astex, AstraZeneca, Ferring, GlaxoSmithKline, J & J Innovation, Pfizer, Shionogi) who are committed to collaboration and...
Start Codon announced as new world-class life science accelerator
This innovative new accelerator programme will provide significant funding and support for selected start-ups, with office and lab space in the Milner Research Labs.
Cancer Research UK and AstraZeneca launch world class functional genomics centre at the Milner Research Labs
Cancer Research UK and AstraZeneca have announced that they are opening a new centre in the Milner Research Labs in Cambridge, dedicated to realising the full potential of functional genomics in the discovery and development of new drugs for patients with cancer. The...
Milner facilitates strategic partnership between Nemesis and Shionogi
SHIONOGI INVESTS IN NEMESIS TECHNOLOGY Japanese Pharma Company Joins £1.4M Seed Funding Round for Nemesis Bioscience Nemesis Bioscience today announced the completion of a Seed funding round of £1.4M from a syndicate of new investors including Shionogi & Co Ltd,...